Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus SODIUM HEPARIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus SODIUM HEPARIN.
HEDULIN vs SODIUM HEPARIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby preventing fibrin formation and extension of thrombi.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
Initial IV bolus 80 units/kg followed by continuous IV infusion at 18 units/kg/hour; adjusted based on aPTT. Alternatively, subcutaneous: 333 units/kg loading dose then 250 units/kg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
Terminal elimination half-life is dose-dependent: 0.5-1.5 hours at low doses, 1.5-2.5 hours at high doses. Clinically, anticoagulant effect half-life is approximately 1-5 hours, with shorter half-life at lower doses.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Renal: negligible; primarily cleared by hepatic and reticuloendothelial system (desulfation and depolymerization). Unchanged drug not excreted in urine.
Category C
Category A/B
Anticoagulant
Anticoagulant